Search

Your search keyword '"Langston, Amelia A."' showing total 912 results

Search Constraints

Start Over You searched for: Author "Langston, Amelia A." Remove constraint Author: "Langston, Amelia A."
912 results on '"Langston, Amelia A."'

Search Results

1. Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD.

2. Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association

6. The Adverse Event Landscape of Stem Cell Transplant: Evidence for aGVHD Driving Early Transplant Associated Toxicities

7. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.

8. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

9. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

10. Passenger pathogens on physicians

11. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

12. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome

13. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

14. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project.

15. Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

16. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

18. P-171 The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients

19. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

20. Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD

21. Abatacept for The Prevention of GVHD in Patients Receiving Mismatched Unrelated Transplants: A Real-World Analysis

26. Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

28. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors

29. Abatacept for the Prevention of Graft Versus Host Disease in Pediatric Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

30. Abatacept for Graft Versus Host Disease Prophylaxis in Patients 60 Years and Older Receiving Mismatched Unrelated Donor Transplantation for Hematologic Malignancies

31. Mechanism of Success of Abatacept in Hematopoietic Stem Cell Transplantation: Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis Demonstrates Greater Abatacept Exposure Decreases Acute Gvhd (AGVHD) Risk without Increasing Adverse Events

32. Real-World Evaluation of Prolonged and Delayed Cytopenias after Chimeric Antigen Receptor T-Cell Therapy: A Comparison of BCMA and CD19 Based Outcomes

33. Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial

35. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire

37. Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

38. Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial

39. Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

40. Passenger pathogens on physicians

45. Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma

48. In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial

49. Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial

Catalog

Books, media, physical & digital resources